Biogen's anti-tau Alzheimer's drug shows 38% slowing of decline at two years
New trial data show the lowest dose of Biogen's experimental tau-reducing drug slowed cognitive decline in early Alzheimer's patients by 38% after two years, with benefits increasing over time.